Coherus Oncology (CHRS) Assets Average (2014 - 2026)
Coherus Oncology (CHRS) posted Assets Average of $262.2 million for Q1 2026, down 32.33% sequentially from $387.4 million in Q4 2025, and down 36.02% YoY from $409.8 million in Q1 2025.
Coherus Oncology (CHRS) Assets Average (2014 - 2026) Analysis & Trends
Coherus Oncology has reported Assets Average for 13 years, with the latest figure at $262.2 million in Q1 2026.
- Quarterly Assets Average fell 36.02% year-over-year to $262.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $262.2 million (down 36.02% YoY) and the FY2025 annual result came in at $353.4 million, down 34.44% from the prior year.
- Assets Average retreated to $262.2 million in Q1 2026 per CHRS's latest filing, from $387.4 million in the prior quarter.
- Over five years, Assets Average peaked at $719.2 million in Q2 2024 and troughed at $262.2 million in Q1 2026.
- A 5-year average of $512.2 million and a median of $515.9 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2025: Assets Average surged 64.95% in 2024, then slumped 43.65% in 2025.
- Over 5 years, Assets Average stood at $515.9 million in 2022, then climbed by 17.6% to $606.7 million in 2023, then dropped by 21.42% to $476.8 million in 2024, then decreased by 18.74% to $387.4 million in 2025, then plunged by 32.33% to $262.2 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $262.2 million, $387.4 million, and $478.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | 228.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 228.60 Mn |
| Mar 31, 2026 | 262.18 Mn |
| Dec 31, 2025 | 387.43 Mn |
| Sep 30, 2025 | 477.99 Mn |
| Jun 30, 2025 | 405.27 Mn |
| Mar 31, 2025 | 409.80 Mn |
| Dec 31, 2024 | 476.77 Mn |
| Sep 30, 2024 | 589.93 Mn |
| Jun 30, 2024 | 719.20 Mn |
| Mar 31, 2024 | 696.57 Mn |
| Dec 31, 2023 | 606.69 Mn |
| Sep 30, 2023 | 526.69 Mn |
| Jun 30, 2023 | 436.01 Mn |
| Mar 31, 2023 | 441.64 Mn |
| Dec 31, 2022 | 515.88 Mn |
| Sep 30, 2022 | 548.46 Mn |
| Jun 30, 2022 | 569.70 Mn |
| Mar 31, 2022 | 636.36 Mn |
| Dec 31, 2021 | 710.53 Mn |
| Sep 30, 2021 | 740.63 Mn |